Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported Gross Margin of 75.97% for Q1 2026, down 321.0% on a YoY basis from 34.38% in Q1 2025, and down 18.73% quarter-over-quarter from 93.48% in Q4 2025.
Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Gross Margin for 5 years, with the latest figure at 75.97% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 321.0% year-over-year to 75.97%; the trailing twelve-month figure through Mar 2026 stood at 96.12% (up 1588.0% YoY), and the FY2025 full-year result was 82.44%, down 127.0% from the prior year.
- Gross Margin for Q1 2026 stood at 75.97%, down from 93.48% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q1 2022, with the low at 265.07% in Q2 2023.
- Historically, Gross Margin has averaged 56.83% across 5 years, with a median of 83.11% in 2024.
- Annual changes were most pronounced in 2023 — Gross Margin tumbled 36507 bps — and 2024, when it soared 34891 bps.
- Atara Biotherapeutics' Gross Margin stood at 100.0% in 2022, then tumbled by 65 bps to 35.19% in 2023, then soared by 125 bps to 79.25% in 2024, then grew by 18 bps to 93.48% in 2025, then decreased by 19 bps to 75.97% in 2026.
- The last three Gross Margin figures came in at 75.97% (Q1 2026), 93.48% (Q4 2025), and 96.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | 75.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.97% |
| Dec 31, 2025 | 93.48% |
| Sep 30, 2025 | 96.67% |
| Jun 30, 2025 | 96.85% |
| Mar 31, 2025 | 79.18% |
| Dec 31, 2024 | 79.25% |
| Sep 30, 2024 | 81.08% |
| Jun 30, 2024 | 83.84% |
| Mar 31, 2024 | 92.74% |
| Dec 31, 2023 | 35.19% |
| Sep 30, 2023 | -22.31% |
| Jun 30, 2023 | -265.07% |
| Mar 31, 2023 | 82.38% |
| Dec 31, 2022 | 100.00% |
| Jun 30, 2022 | 100.00% |
| Mar 31, 2022 | 100.00% |